Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

Status:	Completed
Conditions:	Cancer, Cancer, Blood Cancer, Hematology, Hematology
Therapuetic Areas:	Hematology, Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	2/6/2019
Start Date:	April 30, 2014
End Date:	December 6, 2018

Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

This open-label study is to determine the long-term safety and tolerability of momelotinib in
previously enrolled study participants with primary myelofibrosis (PMF), post-polycythemia
vera myelofibrosis (post-PV MF), post-essential thrombocythemia myelofibrosis (post-ET MF),
polycythemia vera (PV), or essential thrombocythemia (ET), who have tolerated and achieved
stable disease or better with momelotinib treatment while enrolled in a previous clinical
trial.

Key Inclusion Criteria:

- Currently enrolled in study CCL09101E, or YM387-II-02, or successfully completed 24
weeks of study GS-US-352-1672

- Able to comprehend and willing to sign informed consent form

Key Exclusion Criteria:

- Known hypersensitivity to momelotinib, its metabolites, or formulation excipients

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

We found this trial at

sites

Clinical Trial Facility in Frankston Victoria

Frankston, Victoria 3199

from

Frankston,